Curtis AR, Fey C, Morris CM, et al: Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 28:350, 2001.
Cury R, Galhardoni R, Fontoff ET, et al: Effects of deep brain stimulation on pain and other nonmotor symptoms of Parkinson disease. Neurology 83:1403, 2014.
Dabby R, Lange DJ, Trojaborg W, et al: Inclusion body myositis mimicking motor neuron disease. Arch Neurol 58:1253, 2001.
Daniele A, Moro E, Bentivoglio AR: Zolpidem in progressive supra-nuclear palsy. N Engl J Med 341:543, 1999.
Davenport CB: Huntington’s chorea in relation to heredity and eugenics. Proc Natl Acad Sci U S A 1:283, 1915.
de Bie RAM, de Haan RJ, Nijssen PCG, et al: Unilateral pallidotomy in Parkinson’s disease: A randomized, single-blind multicentre trial. Lancet 354:1665, 1999.
de Yébenes JG, Sarasa JL, Daniel SE, Lees AJ: Familial progressive supranuclear palsy. Brain 118:1095, 1995.
Deep-Brain Stimulation for Parkinson’s Disease Group: Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med 345:956, 2001.
DeJong RN: The history of Huntington’s chorea in the United States of America. In: Barbeau A, Klawans HL, Paulson GW, et al (eds): Advances in Neurology. Vol 1: Huntington’s Chorea, 1872–1972. New York, Raven Press, 1973, pp 19–27.
DeKosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity. Ann Neurol 27:457, 1990.
Deonna T: DOPA-sensitive progressive dystonia of childhood with fluctuations of symptoms—Segawa’s syndrome and possible variants. Neuropediatrics 17:81, 1986.
Deuschl G, Schade-Brittinger C, Krack P, et al: A randomized trial of deep-brain stimulation for Parkinson disease. N Engl J Med 355:896, 2006.
Diamond SG, Markham CH, Hoehn MM, et al: Multi-center study of Parkinson mortality with early versus late dopa treatment. Ann Neurol 22:8, 1987.
Doody RS, Raman R, Farlow M, et al: A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369:341, 2013.
Doody RS, Thomas RG, Farlow M, et al: Phase 3 trials of solanezumab for treatment of mild to moderate Alzheimer’s disease. N Engl J Med 370:311, 2014.
Donadio V, Incensi A, Rizzo G, et al: A new potential biomarker for dementia with Lewy bodies. Neurology 89:318, 2017.
Dubois B, Slachevsky A, Pillon B, et al: “Applause sign” helps to discriminate PSP from FTD and PD. Neurology 64:2132, 2005.